Novartis Healthcare/BioTech

Global Regulatory Director, RA Central Solutions CTA/CTR

Basel, Switzerland Hybrid Full-time

Location: Basel (City)

Salary Range

CHF142,100.00 - CHF263,900.00

Job Description Summary

#LI-Hybrid

Location: Basel, Switzerland

Relocation Support: This role is based in Basel, Switzerland. Novartis is unable to offer relocation support: please only apply if accessible.

What if you could shape the future of global clinical trial execution while leading a high-performing team at the forefront of regulatory innovation? As Global Regulatory Director - RA Central Solutions, you will play a pivotal role in ensuring timely, compliant clinical trial applications across a diverse global portfolio. You'll empower and develop talented regulatory professionals, drive operational excellence through process simplification and automation, and influence strategic decisions that strengthen Novartis' ability to bring innovative medicines to patients worldwide.

This is an exciting opportunity to lead meaningful change, build strong cross-functional partnerships, and help create a more agile, future-ready Regulatory Affairs organisation.

Key Responsibilities

  • Lead global clinical trial application activities, ensuring high-quality, compliant submissions and approvals worldwide in collaboration with RA DU Lead.
  • Build, develop and inspire a high-performing regulatory team through coaching, mentoring and talent development.
  • Allocate resources strategically to deliver clinical trial milestones efficiently across the assigned portfolio.
  • Drive process simplification, automation and continuous improvement to enhance operational excellence.
  • Partner with senior stakeholders to shape strategy and support key regulatory business priorities.
  • Foster strong cross-functional collaboration and a customer-focused culture across Regulatory Affairs.
  • Champion organisational change, promoting Novartis values, innovation and knowledge-sharing across teams.

Job description provided by Novartis.
View the original posting